Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising cancer combo trial halted after just 2 patients

NCT ID NCT06939036

Disease control Sponsor: Ariceum Therapeutics GmbH Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested a radioactive drug called 225Ac-SSO110 combined with standard immune checkpoint inhibitors for people with advanced small cell lung cancer or Merkel cell carcinoma. The goal was to check safety and find the right dose. However, the trial was terminated early after enrolling only 2 participants, so no meaningful results are available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
225Ac-SSO110 (a radioactive drug) plus standard immune checkpoint inhibitors
What this could lead to
If it had worked, this could have pointed toward a new treatment option for people with advanced lung or skin cancer.
What could go wrong
The trial was terminated early with only 2 participants enrolled, so no conclusions can be drawn. The approach is very early-stage and may not be safe or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

2 people

The number who actually took part.

Started

Jul 2025

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Signed Informed Consent Form and willing to comply with all study procedures. * Participants with ES-SCLC (defined as Stage IV per NCCN guidelines Version 1.2024) or recurrent locally advanced or metastatic MCC (per NCCN guidelines Version 1.2024) documented by histology or cytology. * Participants eligible to receive immune checkpoint inhibitor (CPI) monotherapy at the start of treatment with 225Ac-SSO110 or patients already on CPI monotherapy for 7 weeks. * ECOG performance status of 0 or 1. Life expectancy of at least 6 months. * Positive 68Ga-SSO120 scan (Investigator-assessed) during screening. Key Exclusion Criteria: * Participants with unstable spinal cord compression. * Any previous systemic radioligand therapy or extensive radiotherapy. * Participants receiving or planned to receive consolidative chest radiation. * History of primary immunodeficiency, transplantation or CAR-T cell therapy. * Major surgical procedure except diagnostic biopsy within 28 days prior to enrolment or scheduled to have major surgery during the study. * Inadequate organ or marrow function.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Merkel cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cutaneous neuroendocrine carcinoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Merkel cell carcinoma Small cell lung cancer extensive stage

Contacts and locations

Locations

  • Biogenix Molecular

    Miami, Florida, 33165, United States

  • GenesisCare

    Alexandria, Australia

  • John Theurer Cancer Center at Hackensack UMC

    Hackensack, New Jersey, 07601, United States

  • UPMC

    Pittsburgh, Pennsylvania, 15219, United States

  • United Theranostics

    Glen Burnie, Maryland, 21061, United States

  • University of Louisville Health-Brown Cancer Center

    Louisville, Kentucky, 40202, United States

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.